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Glossary 
 
AALSRS - Appel Amyotrophic Lateral Sclerosis Rating Scale 
ALS – amyotrophic lateral sclerosis 
ALSAQ-40 – 40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire 
ALSAQ-5 – 5-item Amyotrophic Lateral Sclerosis Assessment Questionnaire 
ALSFRS - Amyotrophic Lateral Sclerosis Functional Rating Scale 
ALSFRS-R - Amyotrophic Lateral Sclerosis Functional Rating Scale revised 
ALSQoL - Amyotrophic Lateral Sclerosis Specific Quality of Life 
ALSSS - Amyotrophic Lateral Sclerosis Severity Scale 
AMPA – alfa-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
ASO - antisense oligonucleotides 
BMI - body mass index 
C9orf72 - chromosome open reading frame 72  
CAFS - Combined Assessment of Function and Survival 
CGI - Clinical Global Impression 
CGI – clinical global impression 
CNS – central nervous system 
CT – clinical trials 
EEC – El Escorial criteria 
EIM - Electrical Impedance Myography 
EMA – European Medicines Agency 
EUDRACT – European clinical trials database 
FALS - familial amyotrophic lateral sclerosis 
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FEV – forced expiratory volume 
FEV1 - forced expiratory volume in one second 
FTLD - frontotemporal lobar dementia 
FVC – forced vital capacity 
HHD - hand-held dynamometry 
IMV - invasive mechanical ventilation 
LMN – lower motor neurons 
MCID - minimal clinically important difference 
MIP - maximal inspiratory pressure 
MMT – manual muscle testing 
MMV - maximum voluntary ventilation 
MND- motor neuron disease 
MRC – Medical Research Council 
MRI – magnetic resonance imaging 
mRNA – messenger-ribonucleic acid 
MUNE - Motor Unit Number Estimation 
MVIC - Maximum Voluntary Isometric Contraction 
MVV - Maximum voluntary ventilation 
NGT - nasogastric tube 
NIV - non-invasive ventilation 
NMDA - N-methyl-D-aspartate 
PEF - peak expiratory flow 
PEG - percutaneous endoscopy gastrostomy 
PImax - maximal inspiratory pressure 
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PRG - percutaneous radiologic gastrostomy  
RCT – randomized clinical trials 
rhEPO – recombinant human erythropoietin 
RNAi - RNA interference 
SALS – sporadic amyotrophic lateral sclerosis 
SNIP – sniff nasal-inspiratory pressure 
SOD 1 - superoxide dismutase 1  
SVC – slow vital capacity   
TQNE – Tufts Quantitative Neuromuscular Exam 
TUDCA – tauroursodeoxycholic acid 
UDCA – ursodeoxycholic acid 
UMN - upper motor neurons  
US FDA – United States Food and Drug Administration 
VAS – visual analogue scale 
VC – vital capacity 
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Resumo 
A Esclerose Lateral Amiotrófica (ELA) é uma doença degenerativa do neurónio motor, que 
apresenta elevada morbilidade e é virtualmente sempre fatal. Por ausência de cura, a abordagem 
terapêutica foca-se na manutenção da qualidade de vida e no seu prolongamento. Nos últimos 50 
anos, todos os ensaios clínicos de fase III, com excepção do Riluzole, não comprovaram eficácia. 
A maioria destes resultados negativos deveu-se à falta de significado estatístico. O objectivo deste 
artigo é discutir se as diferenças obtidas nos instrumentos de eficácia usados nos ensaios clínicos 
mais recentes teriam tido significado clínico para o doente. Realizou-se uma análise descritiva de 
estudos da história natural, ensaios clínicos de fármacos testados e artigos de revisão sobre os 
instrumentos de eficácia dos resultados. Pequenos efeitos positivos, que poderiam ter um enorme 
valor numa doença com tão mau prognóstico como a ELA, podem ter sido negligenciados. Tão 
importante quanto determinar e alcançar a diferença clínica minimamente significativa para a 
sobrevivência e medidas funcionais – para as quais a perspectiva do doente também deveria ser 
tida em conta, dever-se-iam priveligiar os Questionários de Qualidade de Vida enquanto 
instrumentos de eficácia nos ensaios clínicos dado que, por serem subjectivos, são os que melhor 
traduzem o que o doente sente ter maior significado para si.  
 
Abstract  
Amyotrophic Lateral Sclerosis is a progressive degenerative motor neuron disease, with 
significant morbidity and virtually always fatal. There is no cure yet, so care is aimed at 
maintaining quality of life and prolonging life. Over the past half-century, all phase III clinical 
trials have failed to show efficacy, with the exception of Riluzole. Most of the negative results in 
clinical trials are due to the lack of statistical significance. The purpose of this article is to discuss 
whether or not the differences obtained on therapeutic efficacy measures of the most recent failed 
clinical trials would be meaningful to the patient. A descriptive analysis was performed for natural 
history studies, clinical trials of tested agents and review articles of outcomes measures. Small 
positive effects, which could be of great value in a disease with such poor prognosis as ALS, may 
have been missed. As important as determining – that should also be based on the patients’ 
perspective – and reaching the minimal clinical important difference for survival and functional 
measures, a greater attention should be paid at Quality of Life Assessment Questionnaires as a 
key endpoint of efficacy on CT, as these are subjective instruments that may better reflect what 
patients feel to be meaningful. 
 
Keywords: amyotrophic lateral sclerosis • clinical trials • efficacy endpoints • outcome measures • minimal clinical 
importance difference • statistical significance   
Afinal que diferença clínica tem significado no tratamento farmacológico da Esclerose Lateral Amiotrófica - Contributo dos ensaios 
clínicos e análise dos endpoints de eficácia 
 
7 Trabalho final de Mestrado Integrado em Medicina Filipa Taborda 
   
Introduction  
More than 50 randomized controlled 
clinical trials of potential drugs for 
Amyotrophic Lateral Sclerosis (ALS) 
have failed to show positive results in the 
past half-century. [1] Ideally, phase III 
trials are expected to yield positive 
results, as they are performed only after 
evidence of potential efficacy is gathered 
from preclinical research and phase II 
studies. [2] However, the transition from 
phase II to phase III trials remains 
particularly challenging. The lack of 
statistically significant results might lead 
us to ignore a potential effect measured 
by the efficacy endpoints. The purpose 
of this article is to compare the variations 
obtained on therapeutic efficacy 
measures to their expected variation in 
the natural history of the disease, without 
any pharmacological intervention and to 
discuss whether or not these results 
would be meaningful to the patient. 
Amyotrophic Lateral Sclerosis  
ALS is a progressive degenerative motor 
neuron disease characterized by focal 
weakness of limb and bulbar muscles 
that ultimately involve all skeletal 
muscle and lead to the loss and 
dysfunction of both upper and lower 
motor neurons (UMN and LMN, 
respectively). Although rare, ALS is the 
most common form of motor neuron 
disease (MND). Incidence rates for ALS 
in the United States and most European 
countries range from 1.5-2.5 ALS cases 
per 100,000 person per year, according 
to the ALS consortium of Epidemiologic 
Studies. Incidence increases with age, 
peaking between the ages of 50 and 75 
years and declining thereafter [3] with an 
average age of onset of 61,8 years [4].  
The majority of the patients have no 
family history and are termed sporadic 
ALS (SALS). [5] Its main causes and 
molecular basis are still unknown even 
though it seems to have both genetic and 
environmental influences [6] [7]. Ten to 
15% of patients have familial ALS 
(FALS) based on the presence of a 
heritable cause. Clinically, FALS and 
SALS are indistinguishable, although 
patients with familial disease may be 
younger at onset and have more 
protracted disease. Men have higher 
incidence of sporadic disease whereas 
FALS, given autosomal dominant 
inheritance, affects men and women 
equally. [5] 
The most frequent genetic causes of ALS 
are: mutations in the chromosome open 
reading frame 72 (C9orf72) gene, 
accounting for approximately 40% of 
FALS and 5-6% of SALS cases; the 
superoxide dismutase 1 (SOD1) gene, 
which is present in 20% of FALS cases; 
the fused in sarcoma gene, found in 5% 
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of the patients with familial disease; and 
the TAR DNA-binding protein 43 gene, 
affecting 3% of the patients with FALS. 
[8] [4] In rare circumstances, the disease 
is associated by mutations in other genes. 
As motor neurons are affected 
segmentally and to varying degrees in 
different patients, the symptomatology is 
diverse and the initial clinical 
presentation varies considerably. [3]  
The disease affects LMNs arising from 
the brainstem or “bulbar” region, more 
specifically in the medulla, and from the 
anterior horn of grey matter of the spinal 
cord as well as UMNs in the cerebral 
cortex.  Fasciculation, cramps, muscle 
atrophy and marked weakness are the 
main LMN signs and may be focal, 
multifocal or diffuse. Hyperreflexia, 
spasticity, Babinski sign, snout reflexes, 
incoordination and weakness are typical 
of UMN degeneration. [9] [7] 
The bulbar signs are caused by the 
involvement of the somatic nuclei of the 
VII, IX and XII cranial nerves. Patients 
present dysarthria, that may progress to 
anarthria, dysphagia, drooling and an 
atrophied fasciculating tongue that is 
very characteristic of bulbar ALS and 
virtually diagnostic of the condition.[9] 
[7] 
ALS begins in the limbs in about two-
thirds of patients, most often in the arms. 
The first symptoms are usually unilateral 
and focal. Early findings include foot 
drop, difficulty walking, loss of hand 
dexterity or difficulty lifting the arms 
over the head. Eventually, limb function 
can be lost. About 30% of patients, 
typically older woman, have bulbar-
onset disease and 5-10% present with 
more generalized symptoms. [5] [3] [7] 
Classically, despite the site of onset, 
ALS spreads to contiguous, and 
eventually respiratory, myotomes. [7] 
Axial weakness can cause dropped head 
and kyphosis, features associated with 
pain and poor balance. [7] 
Extraocular and sphincter muscles are 
characteristically spared in patients with 
ALS, at least until late in the disease [3] 
and sensory symptoms are rare. 
Clinically, ALS is a pure motor neuron 
syndrome. [9] [3] 
A significant number of ALS patients 
have cognitive impairment. 
Frontotemporal dysfunction and 
atrophy, as seen in frontotemporal lobar 
dementia (FTLD), occurs in up to 50% 
of patients, which can present with 
subclinical executive, language or 
behaviour dysfunction or, in a smaller 
percentage of cases (15%), meet the 
formal criteria for the behavioural 
variant of FTLD, or the non-fluent or the 
semantic variant of primary progressive 
aphasia [8] [9]. Personality change, 
irritability, impaired judgement, 
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impulsivity and pervasive deficits on 
frontal executive tests are the 
commonest manifestations. [3] 
Morning headache, weakened cough, 
orthopnoea and exertional dyspnoea are 
early respiratory symptoms. [7] 
The diagnosis depends on progressive 
UMN and LMN findings on history and 
examination. Electromyography 
confirms widespread LMN disease and 
excludes other conditions, such as 
multifocal motor neuropathy with 
conduction block. Brain and spinal MRI 
exclude conditions that affect the UMN 
such as cervical spondylosis. [7] These 
are the two conditions most commonly 
mistaken for ALS. [3] 
Occasionally, brain MRI shows bilateral 
signal changes in the corticospinal tracts, 
a finding that is pathognomic of ALS.   
Progressive LMN disease by clinical and 
electromyographic examination, and 
clinical UMN signs are, therefore, the 
core hints for the diagnosis of ALS. The 
Revised El Escorial Diagnostic Criteria 
for Amyotrophic Lateral Sclerosis 
establish the degree of certainty of 
diagnosis and facilitates timely 
enrolment in clinical trials and patient-
oriented research.  [7] [3] 
The clinical, pathological and genetic 
advances indicate heterogeneity in 
phenotype, pathological substrate and 
genetic predisposition, suggesting that 
ALS should be considered a syndrome 
rather than a single disease entity. [3] 
Indeed, a number of distinct clinical 
phenotypes exist within the ALS disease 
spectrum, and may be associated with 
rates of disease progression that differ 
from those of more typical ALS. Flail-
limb variant, along with other LMN-
predominant subtypes and pure motor 
neuron conditions may be characterized 
by slower disease progression [10] [3]. It 
is common to admit that lower-limb 
onset carries a better prognosis than the 
upper-limb onset [3]. However, there are 
conflicting data on this subject as some 
studies showed a poorer prognosis with 
lower limb onset, presumably due to an 
increase risk of thromboembolic disease 
and infections arising from loss of 
motility [11]. Bulbar and respiratory-
onset disease carries the worst prognosis.  
[3] 
Older age (>65), a rapid decline in 
ALSFRS-R score, psychological 
distress, coexistence with 
frontotemporal lobar dementia (FTLD), 
a lower FVC at diagnosis or FVC <50%, 
SNIP <40 and definite-EEC diagnosis 
are all poor prognostic indicators. [11] 
A longer delay from symptom onset to 
diagnosis is a good prognostic factor 
since a short time delay may indicate a 
more aggressive disease that led the 
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patient to seek medical attention more 
rapidly. [11] 
Finally, hyperlipidemia and a higher pre-
morbid body mass index (BMI) with the 
maintenance of BMI and nutritional state 
along the course of the disease has been 
associated with improved outcome, with 
the optimal values of BMI being between 
30 and 35 kg/m2. [12] 
There is no cure yet for ALS, so care is 
aimed at maintaining quality of life and 
prolonging life as much as possible. [7] 
Multidisciplinary care should be 
provided to all people affected with 
ALS. Currently treatment focuses 
mainly on symptomatic treatment, 
respiratory and nutritional therapies and 
on the only disease-modifying treatment 
available, riluzole.  
Respiratory complications are the main 
cause of death in ALS, primary as 
consequence of diaphragmatic weakness 
combined with aspiration and infection 
due to excess secretions and poor airway 
clearance. Non-invasive ventilation 
(NIV), usually with a bi-level 
intermittent positive-pressure ventilator, 
is the standard intervention for patients 
with respiratory insufficiency and should 
be preferred to invasive mechanical 
ventilation (IMV), which should be used 
as a last resource. Cough-assist devices 
and chest wall oscillation can also be 
offered to increase the effectiveness of 
assisted ventilation in ALS. Medical 
treatment of chronic or intermittent 
dyspnea is recommended. Pneumonia 
and influenza vaccines are of value as 
prophylactic measures.   
Weight loss at time of diagnosis is an 
independent prognostic factor of 
survival in ALS and is a consequence of 
an increased resting energy expenditure 
and decreased ingestion of food due to 
dysphagia. The initial management is 
based on dietary counseling, 
modification of food and fluid 
consistency, high-protein and high-
caloric supplements and education of 
feeding and swallowing techniques. 
When tube feeding is needed, there are 
three procedures that obviate major 
surgery: percutaneous endoscopy 
gastrostomy (PEG), percutaneous 
radiologic gastrostomy (PRG) and 
nasogastric tube (NGT) feeding, usually 
used in the short-term and when PEG or 
PRG are not suitable. The timing of 
PEG/PRG is based on an individual 
approach taking into account bulbar 
symptoms, mal-nutrition, respiratory 
function and the patient’s general 
condition. Early insertion of a feeding 
tube is recommended. Home parenteral 
nutrition is possible as an alternative to 
enteral feeding in patients with advanced 
ALS and poor respiratory function.  
Afinal que diferença clínica tem significado no tratamento farmacológico da Esclerose Lateral Amiotrófica - Contributo dos ensaios 
clínicos e análise dos endpoints de eficácia 
 
11 Trabalho final de Mestrado Integrado em Medicina Filipa Taborda 
   
Medications to relieve suffering and 
dyspnea, including anxiolytics and 
opioids, can be prescribed.    
In addition to the significant morbidity, 
the disease is virtually always fatal and 
on average, death from respiratory 
failure secondary to diaphragmatic 
paralysis occurs within 3-4 years from 
the onset of symptomatic weakness. [13] 
[14]  
Survival ranges from months to decades 
with approximately 10% of patients 
surviving more than 10 years from the 
time of diagnosis. [5] [6]   
Methods  
A search in PubMed for English or 
Portuguese-language review articles or 
phase II and III clinical trials, was 
performed, from the past 5 years and 
only in humans, using the search terms 
“amyotrophic lateral sclerosis” or 
“motor neuron disease” in combination 
with “drug therapy” and “outcome 
measures”. Time restriction was due to 
the boom of phase II and III CTs 
concerning this subject in the past five 
years, and previous studies lacked 
methodological robustness. Further 
relevant material were included from 
reference lists as well as from the 
European and American Guidelines on 
the clinical management of Amyotrophic 
Lateral Sclerosis, EMA Guideline on 
clinical investigation of medical 
products for the treatment of ALS and 
from the websites of clinicaltrials.gov 
and EUDRACT.   
A descriptive analysis was performed 
for: 
 Natural history studies, 
describing disease progression; 
 Trials on approved medication; 
 Trials on previously tested 
agents; 
 Review articles of outcomes used 
for the assessment of efficacy in 
ALS. 
The progression of the outcome 
measures in the placebo arm of riluzole’s 
clinical trials was also used to assess 
their variation in the natural history. 
All the drugs tested in the past five years 
were included in this analysis as well as 
riluzole, as it is the only approved drug 
to date. 
Results 
 
Disease-modifying therapies for ALS 
Current experimental ALS drugs are 
being developed on the basis of 
presumed pathophysiologic 
mechanisms. The most accepted 
hypotheses concerning disease 
pathophysiology include glutamate-
mediated excitotoxic effects, oxidative 
stress, proteosomal dysfunction, protein 
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misfolding and accumulation, axonal 
transport abnormalities, mitochondrial 
dysfunction, glial activation with a 
micro-inflammatory process and 
aberrant neurotrophic/growth factor 
signalling. [15] 
The key used outcomes and the results 
obtained from the drug trials consulted 
are presented in the table 1.  
Over the last 25 years, despite significant 
effectiveness of potential therapeutics 
observed in preclinical trials, all phase 
III clinical trials have failed to show 
efficacy, with the exception of Riluzole. 
[6] [13] 
There is a long list of agents with 
disappointing results in ALS, which 
could be grouped into the following 
eleven categories (by its shared 
mechanism of action): anti-
glutamatergic agents, antioxidant 
therapy, agents targeting autophagy, 
anti-apoptotic agents, drugs targeting 
protein misfolding and accumulation, 
mitochondrial agents, 
immunomodulatory agents, neurotrophic 
factors, agents promoting mutant mRNA 
counteraction, stem-cell therapy and 
muscle-directed therapy. 
More recently, much attention has been 
focused on stem-cell therapy, antisense 
oligonucleotides (ASO) and RNA 
interference (RNAi) as a very promising 
land of future disease-modifying 
therapies. 
Riluzole  
Until the early 1990s, all clinical trials of 
disease-specific therapy for ALS yielded 
unfavourable results. Emerging evidence 
that chronic glutamate excitotoxicity 
might accumulate to toxic levels and 
contribute to neuronal death in ALS 
provided a rational basis for undertaking 
a clinical trial with riluzole [14], a 
benzothiazole derivative that possesses 
anti-glutamatergic properties. [16] 
Riluzole has complex effects and the 
means trough which it influences 
neurodegeneration in ALS are not fully 
elucidated. The chief mechanism 
appears to be via the reduction of 
glutamate levels at the synaptic cleft [16] 
by enhancing the uptake of ambient 
glutamate by astrocytes as well as 
presynaptic glutamatergic nerve 
terminals and reducing the endogenous 
release of glutamate particularly  from 
very active synapses [17]. It may also 
exert neuroprotective action trough non-
competitive post-synaptic inhibition of 
NMDA and AMPA receptors [16] and 
inhibition of a persistent Na+ current that 
support long-lasting firing of action 
potentials by motor neurons. This 
depressant effect by riluzole limits 
neuronal excitability and restricts the  
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Table 1. Contribute of the clinical trials of riluzole and of the agents with studies posted in the past 5 years in the analyses of the 
variation of the key outcomes. (part 1/6) 
 
 
 
 
 
 
 
  Agent Study design Key outcome Results  
1
. 
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R
G
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N
T
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 Riluzole 
 
Prospective, 
multicentre, double-
blind, randomized,  
placebo-controlled,  
parallel group trial [28] 
 
155 patients  
 
21 months 
 
 
study 216 
Primary 
Survival (death from any 
cause and tracheostomy) 
Functional status - modified 
Norris Scales 
 
Secondary 
MRC  
FVC 
Clinical Global Impression 
of Change scale 
Riluzole therapy reduced 
mortality by 38.6% at 12 
months and by 19.4% at 21 
months – an effect both 
clinically important and 
statistically significant  
 
12-month survival: 58% 
(placebo) vs 74% (riluzole) 
p = 0.014 
 Bulbar-onset 
disease: 35% 
(placebo) vs 73% 
(riluzole)  p = 0.014 
 Limb-onset disease: 
64% (placebo) vs 
74% (riluzole)  p = 
0.17 
 
21-month survival: 37% 
(placebo) vs 49% (riluzole) 
p=0.046  
 Bulbar-onset 
disease: 18% 
(placebo) vs 53% 
(riluzole) p=0.0.13 
 Limb-onset disease: 
43% (placebo) vs 
48% (riluzole)  p = 
0.355 
 
Median survival was 449 
days (placebo) vs 532 days 
(riluzole) 
 
For each functional score, 
the rate of deterioration was 
slower in the riluzole group 
 Only the 33.4% 
reduction in the 
rate of 
deterioration of 
muscle function at 
12 months was 
statistically 
significant  p = 
0.028  
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Table 1. Contribute of the clinical trials of riluzole and of the agents with studies posted in the past 5 years in the analyses of the 
variation of the key outcomes. (part 2/6) 
1
. 
A
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R
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G
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 Riluzole  
 
Multicentre, double-
blind, placebo-
controlled, randomized, 
parallel group, dose 
ranging study[29] 
 
959 patients 
 
18 months 
 
 
study 301 
Primary: 
Survival without tracheostomy 
 
Secondary: 
MRC 
Modified Norris Scales 
VC   
Clinical Global Impression scale 
Visual Analogue Scales (for 
fasciculations, cramps, stiffness, 
tiredness) 
 
50.4% of the patients alive 
at study end (placebo) vs: 
 55.3% (50mg 
riluzole) 
 56.8% (100mg 
riluzole) 
 57.8% (200mg 
riluzole) 
After adjustment for 
prognostic factors, there 
was a significant overall 
drug effect at 12 and 18 
months. Survival was 
greater with each riluzole 
dose that with placebo.  p 
= 0.04,  p = 0.002, p = 
0.0004 for the increasing 
doses 
 
At 18 months, the 50 mg, 
100mg and 200mg riluzole 
doses decreased the risk of 
death or tracheostomy by 
24%, 35% and 39%, 
respectively. 
 
Muscle-strength testing, 
limb or bulbar scores 
without evidence of a 
treatment effect.  
 
No other treatment effect 
was detectable with 
respiratory function tests, 
visual analogue scales or 
CGI 
 
 
Multicentre, double-
blind, randomized, 
placebo-controlled, 
parallel group trial  
(study 302) – advanced 
stage disease or aged 
over 75 years [30] 
 
168 patients 
 
18 months 
 
study 302 
Primary: 
Survival  
 
Secondary: 
MMT scale 
Modified Norris bulbar and 
limb scales 
Clinical Global Impression 
Scale 
Visual Analogue Scales (for 
fasciculations, cramps, stiffness, 
tiredness) 
FEV, SVC   
Not enough patients to 
reach adequate power to 
detect differences in 
survival. 
 
Survival at 18 months: 
25.6% (placebo) vs 26.8% 
(riluzole)  p = 0.77 
 
No differences in the rate 
of deterioration of MMT 
 
Rate of deterioration of the 
score of the Norris bulbar 
scale significantly lower 
(riluzole).  p = 0.05 
 
No significant difference 
among groups for CGI, 
parameters of VAS or in 
respiratory function – data 
not shown.  
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Table 1. Contribute of the clinical trials of riluzole and of the agents with studies posted in the past 5 years in the analyses of the 
variation of the key outcomes. (part 3/6) 
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Ceftriaxone 
Multi-phase (phase I-III) 
randomized, double-
blinded, placebo 
controlled trial [2] 
 
514 patients 
 
6 years 
 
NCT00349622 
Co-primary  
Survival  
ALSFRS-R 
 
Secondary 
Changes from 
baseline in Vital 
Capacity 
Changes in upper- 
and lower-limb 
muscle strength using 
Hand Held 
Dynamometry 
ALSQoL 
 
 
During stage I and II:  
 
ALSFRS-R functional 
decline 0.51 +/- 0.24 units 
per month slower in 
ceftriaxone group. p = 
0.0416 
 
No differences noted for 
VC.  
Leg strength declined at a 
slower rate. 
 
Stage III: Failed to show 
efficacy 
 
ALSFRS-R functional 
decline 0.09+/- 0.08 units 
per month slower.   p = 
0.2370 
 
HHD difference in slopes 
was 0.038+/-0.0192 units 
per month.   p = 0.0550 
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Talampanel  
Phase II multicenter, 
randomized, double-
blinded, placebo 
controlled [31] 
 
59 patients 
 
9 months  
 
 
NCT00696332 
Primary 
TQNE arm strength 
megaslope 
 
Secondary 
TQNE leg strength 
megaslope 
VC 
ALSFRS  
Timed hand function 
score   
survival 
Slower decline in ALSFRS-
R (less 30%)   p = 0.081 
 Change from 
baseline at 9 
months of -7.1 in 
the talampanel 
group vs -10.1 in 
the placebo group 
 
Slower decline in isometric 
arm strength (less 15%)    
p = 0.840 
 TQNE arm strength 
declined 1.9 
units/year in the 
talampanel group 
vs 2.2 units/year in 
the placebo group 
 
TQNE leg strength declined 
1.4 units/year (talampanel 
group) vs 1.3 units/year 
(placebo group)   p = 0.971 
 
TQNE timed hand function 
declined 1.0 unit/year 
(talampanel group) vs 1.5 
units/year (placebo group)   
p = 0.123 
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Table 1. Contribute of the clinical trials of riluzole and of the agents with studies posted in the past 5 years in the analyses of the 
variation of the key outcomes. (part 4/6) 
 
 
 
 
2
. 
A
N
T
I-
O
X
ID
A
N
T
 T
H
E
R
A
P
Y
 
 Pioglitazone 
Double-blind, 
randomized, 
placebo-
controlled, 
multicenter phase 
II trial [32] 
 
219 patients 
 
2 years 
 
NCT00690118 
Primary 
Survival  
 
Secondary 
Incidence of 
tracheotomy and of 
NIV 
ALSFRS-R 
Slow vital capacity  
EUROQoL EQ-5D 
Hazard for death was increased of 21% 
in the pioglitazone group.   p = 0.48 
 
Incidence of tracheotomy 6.4% 
(pioglitazone group) vs 4.6% (placebo 
group)   p = 0.54 
 
Incidence of NIV 20.2% (pioglitazone 
group) vs 26.6% (placebo group)  
p = 0.28 
 
Small difference in ALSFRS-R score ( 
2 points) at 15 months with pioglitazone   
p = 0.66 and not sustained  
 
Slope of EUROQoL EQ-5D and SVC 
not affected by pioglitazone (not shown) 
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 Lithium Carbonate 
Double-blind, 
randomized, 
placebo-
controlled, 
multicenter phase 
III trial[33] 
 
243 patients 
 
Ongoing  
 
EudraCT 2008-
006891-31 
 
Primary 
Rate of survival at 18 
months 
 
Secondary  
ALSFRS-R 
Mental health state 
measured with 
hospital anxiety and 
depression scale 
EUROQoL EQ-5D 
 
 
Survival at 18 months 59% (placebo) vs 
50% (lithium)   p = 0.20 
 In a post-hoc analysis, after 
adjusting for study centre and 
site of onset, the relative odds 
of survival at 18 months 
(lithium vs placebo) was 0.71 
 
Annual rate of change in ALSFRS-R 
score was 9.47 (placebo) vs 9.75 
(lithium) adjusted for survival  – not 
statistical significant (p value not shown) 
 
HADS anxiety/depression scores at 18 
months of 3.5/4.71 (placebo) vs 
4.55/5.17 (lithium) - the higher the 
scores, the poorer the outcome 
 
EUROQoL EQ-5D score at 18 months of 
61.95 (placebo) vs 56.36 (lithium)  
 
Double-blind, 
randomized, 
placebo-
controlled, 
multicenter phase 
II trial[34] 
 
214 patients 
 
13 months  
 
NCT00790582 
Primary 
Slope of the 
ALSFRS-R 
 
Secondary 
Rate of decline of 
mean FVC 
Quality of Life 
Weight loss  
Estimated mean slope of ALSFRS-R 
score: 1.20/month (lithium) vs 
1.01/month (placebo)  p = 0.04 
 
Mean slope of decline of the FVC: 
2.84/month (lithium) vs 2.91/month 
(placebo)  p = 0.80 
 
Rate of decline of QoL: 0.139/month 
(lithium) vs 0.136/month (placebo)   
p = 0.93 
 
No difference in weight loss 
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Table 1. Contribute of the clinical trials of riluzole and of the agents with studies posted in the past 5 years in the analyses of the 
variation of the key outcomes. (part 5/6) 
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Growth factor 
erythropoietin 
(EPO) 
 
 
Double-blind, 
randomized, 
placebo-
controlled, 
multicenter 
phase III trial[35] 
 
208 patients 
 
18 months  
 
EudraCT 2009-
016066-91 
 
Primary 
Time from 
randomization to 
death, 
tracheotomy or 
>23h NIV (14 
consecutive days) 
 
Secondary 
ALSFRS-R  
SVC  
ALSAQ-40 
questionnaire 
 
Rate of overall events: 25% (rhEPO) vs 23% 
(placebo)  p = 0.88 
 Rate of death 10% (rhEPO) vs 7% (placebo) 
p = 0.52 
 Rate of tracheotomy or >23h NIV 15% 
(rhEPO) vs 16% (placebo) p = 0.77 
Even after stratification by disease severity and onset, 
the rate of events did not differ significantly between 
treatment groups.  
 
Survival probability at 12 months 78% (rhEPO) vs 
73% (placebo) p = 0.99 
 
ALSFRS-R score at 12 months was 28 (rhEPO) vs 26 
(placebo)  p = 0.31 
 
SVC value was approximately 60% (rhEPO) vs 63% 
(placebo) p = 0.47 
 
ALSAQ-40 score at 12 months: +29 points with 
rhEPO vs +37 points with placebo  p = 0.23 
Ursodeoxycholic 
acid 
(TUDCA/UDCA) 
Double-blind, 
randomized, 
placebo-
controlled phase 
II trial[36] 
 
34 patients 
 
54 weeks 
 
NCT00877604 
 
Primary 
Proportion of 
responders 
(improvement of 
at least 15% in 
ALSFRS-R slope) 
 
Secondary 
ALSFRS-R 
Survival time 
FVC at end study 
Quality of Life 
assessed by short 
form 36 (SF-36) 
questionnaire 
MRC scores for 
right and left 
muscle groups 
 
 
Proportion of responders:  87% (TUDCA) vs 43% 
(placebo)  p = 0.021 
 
ALSFRS-R at study end: 23.3 (TUDCA) vs 16.3 
(placebo)  p = 0.007 
 
Comparison of the slopes of regression analysis 
showed slower progression in the TUDCA group  
(-0.262 vs – 0.388)  p <0.01 
 
FVC at end study: 87.7% (placebo) vs 89.1% 
(TUDCA)  p = 0.778 
 
SF-3 at end study: physical component 35.0 (placebo) 
vs 34.8 (TUDCA)  p = 0.951; mental component 42.3 
(placebo) vs 49.0 (TUDCA)  p = 0.173 
 
MRC scale: right muscle group 47 (placebo) vs 49.2 
(TUDCA)  p = 0.695; left muscle group 43.7 
(placebo) vs 47.0 (TUDCA)  p = 0.553 
Double-blind, 
randomized, 
placebo-
controlled, 
cross-over, 
single center, 
phase III trial[37] 
 
63 patients 
 
8 months  
 
KFDA and IRB of 
Seoul National 
University Hospital 
(H-0301-099-007) 
Primary 
Slope of AALSRS 
 
Secondary 
Deterioration rate 
of ALSFRS-R 
Deterioration rate 
of FVC  
 
Slope of AALSRS 2.24 points/month (UDCA) vs 
3.88 points/month (placebo) – 1.63 points/month 
slower while in UDCA group – p = 0.004 but high 
attrition rate 
 
Time to a 20-points progression in AALSRS total 
score was estimated to be delayed by 14.9 months in 
UDCA group (22.5 vs 7.6 months)  p = 0.018 
 
ALSFRS-R slope of 0.97 (UDCA) vs 1.54 (placebo)  
p = 0.22 
 
FVC slope of 0.76 (UDCA) vs 1.90 (placebo) 
p = 0.53 
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Table 1. Contribute of the clinical trials of riluzole and of the agents with studies posted in the past 5 years in the analyses of the 
variation of the key outcomes. (part 6/6) 
 
 
 
spread of network overactivity that 
perpetuates a vicious circle of further  
excessive release of glutamate and 
increased neuronal damage [17] [18].  
Despite its modest effect on survival and 
the lack of a positive effect on functional 
symptoms, riluzole is the only drug  
 
 
 
approved for the treatment of ALS and is 
widely prescribed in clinical practice. 
It was approved by regulatory agencies 
in 1995 following two randomized 
controlled trials, which showed that the 
drug extends survival in ALS. [16] There 
was a third trial, in which patients with 
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Dexpramipexole 
Double-blind, 
randomized, placebo-
controlled, 
multicenter phase III 
trial[38] 
 
943 patients 
 
12 months 
 
 
NCT01281189 
Primary 
CAFS score 
 
Secondary 
Time to death or 
respiratory impairment 
<18 months  
Time to reach <50% 
predicted upright SVC 
or death 
HHD megascore 
change from baseline at 
12 months 
ALSAQ-5 total score 
change from baseline 
ate 12 months 
Mean CAFS score at 12 months: 
441.76 (dexpramipexole) vs 438.84 
(placebo)   p = 0.86 
 change in ALSFRS-R score 
from baseline: 13.34 
(dexpramipexole) vs 13.42 
 
12.35 months (dexpramipexole) vs 
12.06 months to death or respiratory 
impairment for 20th percentile    
p = 0.77 
 
16 months (dexpramipexole) vs 14.1 
months to reach <50% predicted 
upright SVC or death 50th percentile  
p = 0.77 
 
change of HHD megascore from 
baseline -0.73 (dexpramipexole) vs -
0.70   p = 0.56 
 
change of ALSAQ-5 total score from 
baseline: 21.17 (dexpramipexole) vs 
21.35  p = 0.90 
 
Olesoxime 
Double-blind, 
randomized, placebo-
controlled, 
multicenter phase II-
III trial [39] 
 
512 patients 
 
18 months  
 
NCT00868166 
Primary 
18 months’ survival 
 
Secondary 
Rates of deterioration 
of ALSFRS-R (9-
month assessment) 
SVC 
Manual muscle testing 
 
Estimated overall survival 67.5% 
(placebo) vs 69.4% (olesoxime)  
p = 0.71 
 
Small difference in ALSFRS-R 
global score ( 2 points) at 9 months 
in favor of olesoxime – not sustained 
after 18 months’ treatment nor 
evident in either stratified bulbar or 
spinal subpopulations  p = 0.0242 
 
Analyses of the rate of deterioration 
in SVC or in MMT did not detect 
differences between groups. 
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advanced disease or aged over 75 years 
or with vital capacity less than 60% were 
included, that failed to show any effect 
on survival.  
In the three studies, survival, defined by 
patients who were alive, not intubated 
for mechanical ventilation and 
tracheotomy-free, was the primary 
efficacy endpoint. Secondary endpoints 
were functional scales, including the 
Manual Muscle Scale and the Norris 
Scales.  
When the endpoint taken was mortality 
only – excluding tracheotomy and 
intubation – the conclusions did not 
change, since the rate of tracheotomy 
and/or intubation were very low and 
most of these events were followed by 
death before reaching the cut-off date.  
Both the American and European 
Guidelines recommend that all patients 
with ALS should be offered treatment 
with riluzole 50 mg twice daily and that 
treatment should be initiated as early as 
possible after diagnosis. 
 
Outcome measures 
A review of phase III trials performed in 
the last 20 years shows a very restricted 
range of endpoints used. [19] 
Major treatment trials undertaken in 
ALS have focused on survival and other 
clinical endpoints for efficacy analysis.  
As ALS remains a clinical diagnosis, 
clinical measurements strategies are 
intuitive as research endpoints. In fact, 
regulatory approval of new therapies by 
the US FDA and the European Agency 
for the Evaluation of Medicinal Products 
requires evidence of improvement of 
clinical endpoints such as survival, 
function and strength measures. [10] 
The Guidelines on clinical investigation 
of medicinal products for the treatment 
of ALS suggest as Therapeutic Efficacy 
Measures the following ones: survival; 
functional measures, including ALS 
Functional Rating Scale and its revised 
version (ALSFRS-R), the Norris Scale, 
the Appel ALS Rating Scale (AALSRS) 
and the ALS Severity Scale (ALSSS); 
muscle strength measurements using 
composite manual muscle testing 
(MMT) scores, hand-held dynamometry 
(HHD) or more complex quantified 
methods such as measurement of 
Maximum Voluntary Isometric 
Contraction (MVIC); and respiratory 
function measurements using vital 
capacity (VC) obtained through forced 
vital capacity (FVC) or slow vital 
capacity (SVC), peak expiratory flow 
(PEF), forced expiratory volume in one 
second (FEV1), maximal inspiratory 
pressure (PImax), sniff nasal inspiratory 
pressure (SNIP) and maximum 
voluntary ventilation (MVV) test. 
Assessment of Health Related Quality of 
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Life is also a valuable measure of 
therapeutic efficacy, which may be 
applied as a secondary endpoint, as well 
as global measures using physician’s and 
patient’s Clinical Global Impression 
(CGI) scale.   
As described before, for riluzole, which 
is so far the only drug approved to treat 
ALS, survival was the primary outcome 
measure. Subsequent trials have 
employed the functional rating scales 
either the AALSRS, the ALSFRS or the 
ALSFRS-R. In addition, the muscle 
strength measures previously mentioned, 
pulmonary function – primarily using 
vital capacity, but lately also SNIP and 
MVV – and quality of life measures have 
been employed as secondary outcomes. 
More recently introduced as secondary 
measures, there is the Motor Unit 
Number Estimation (MUNE) and 
Electrical Impedance Myography (EIM), 
both independent of the subject 
cooperation. [19] 
To this moment, the most used outcomes 
for primary and key secondary endpoints 
are presented in the table 2 that 
summarizes their expected variation in 
the natural history of the disease and the 
minimal clinically important difference 
(MCID). 
Measuring survival. Improved survival, 
typically defined as survival without 
tracheostomy or permanent assisted 
ventilation, is clearly an important 
objective for a proposed treatment for 
ALS [10]. Even though it seems to be an 
endpoint that reflects underlying disease 
progression, careful consideration 
suggests that it may be impacted by 
many factors independent of progression 
rate. For instance, the use of the 
diaphragm pacing system seems to exert 
a dramatic increase in survival but has no 
effect on the underlying disease 
progression [19].  
The definition of its MCID is still 
controversial and a 3-month increase in 
survival of patients with ALS with no 
improvement in function has been 
judged by many as less than a MCID. 
[20] 
Therefore, even though riluzole is 
approved for the treatment of ALS, its 
clinical relevance remains debatable and 
raises ethical issues due to the limited 
benefit on its primary endpoint, 
extending survival only 2-months. 
Functional assessments. The AALSRS 
and ALSFRS both in their original and 
revised forms assess multiple aspects of 
patient function, including bulbar 
function, gross and fine motor function, 
and respiratory status. They all change 
systematically with progression, and rate 
of change in these measures correlates 
well with survival. [19]  
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Table 2. Therapeutic Efficacy Measures: expected variation with natural history and MCID. (part 1/2) 
  
Therapeutic Efficacy 
Measures 
Δ Natural history (no intervention) Clinically 
Meaningful 
Effect 
 
Survival 
 
58% alive at 12 months[28] 
 Bulbar-onset disease 35% alive at 12 months 
 Limb-onset disease 64% alive at 12 months 
 
Median survival 449 days[28] 
 Bulbar-onset disease 239 days 
 Limb-onset disease 523 days 
 
Improved survival over time in placebo controlled participants 
enrolled in clinical trials. [40] 
 
Median survival 2-4 years from symptom onset [41-43] 
 
Median survival 33.6 months from first symptoms [41] 
 
3-month 
increase in 
survival 
(controversial) 
Functional 
Measures  
ALSFRS-R  
According to different studies: 
 
1 point/month [44] 
0.92 points/month [21] 
0.7 to 1 point/month [40] 
 
A reduction of 
20% or 
greater in the 
slope of the 
score 
Norris Scale 
 
 
Mean rate of deterioration per year [28]: 
 Limb functional score: 28.1% 
 Bulbar functional score 12.3% 
 
Not known 
AALSRS  
 
Slopes range from 0 to 30 points/month change in total score [41] Not known 
ALSSS 
Not known Not known 
Combined 
Assessment 
of Function 
and Survival 
(CAFS) 
Not known Not known 
Muscle 
Strength 
Measurements 
MMT scores 
 Mean rate of deterioration per year: 34.4%  [28] Not known 
HHD  
Not known Not known 
MVIC Mean rate of decline of MVIC arm megascore (units/month) [40]  -0.05 
to 0.1 
  
Mean rate of decline of MVIC grip megascore (units/month) [40] -0.06 
to 0.1 
 
Not known 
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Table 2. Therapeutic Efficacy Measures: expected variation with natural history and MCID. (part 2/2) 
 
 
 
The changes in slope of decline in 
ALSFRS/ALSFRS-R do not necessarily 
imply disease modification. [19]  
A clinically meaningful effect is 
achieved, for ALSFRS-R, with a 
relatively good consensus among 
researchers, when there is a change of 
20% or greater in the slope of the score 
[21]. 
Although ALSFRS-R is the most widely 
used surrogate marker of disease 
progression, there are recent metric 
analyses of the scale that show it fails to 
satisfy rigorous measurement standards 
and that should be, at least in part, 
revised. In these analyses, good internal 
consistency was shown but it lacked 
unidimensionality, with ambiguous 
interpretation of the total score that does 
not represent a single attribute [22]. The 
clinical heterogeneity distorts the link 
between total score and disease severity 
[10]. 
 
 
 
Collapsing the scale’s 5 level rating into 
3 levels improved its metric quality but, 
at present, ALSFRS-R should be 
considered as a profile of mean scores 
from three different domains (bulbar, 
motor and respiratory function) more 
than a global total score. [22] 
Furthermore, it is demonstrated that 
clinical factors significantly influences 
ALSFRS-R decline, including the age of 
onset, phenotype, body mass index, 
progression rate at diagnosis, degree of 
diagnostic certainty according to 
Revised EEC and FVC% at diagnosis, 
some of which are also independent 
prognostic factors for ALS survival. [23] 
The higher the heterogeneity of disease 
progression, the lower the power to 
detect significant differences in clinical 
trials [23]. These data emphasize that 
ALSFRS-R would need an expert 
revision before it can be appropriately 
used as a primary or secondary outcome 
Respiratory 
Function 
Measurements 
 
VC/ FVC/ 
sVC 
3% per month [19] 
 
Mean rate of decline of %VC (units/month) [40] -1.1 to -2.8% 
Δ 20% in 
FVC117 
 
PI max 
Not known Not known  
 
SNIP 
Decline 13.52% (+/- 25.84)  at 5.2 months [45] Not known 
MVV 
Rate of decline of 4% per month [19] Not known 
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measure of efficacy in future therapeutic 
trials as a proxy of disease progression 
[24].  
Despite these limitations, it is a 
measurement with a clinically 
meaningful index established, that 
implies minimal training requirements 
and has universal applicability. [10]  
Combined endpoints have been used in 
other diseases to decrease the 
confounding effect of mortality on 
analysis of functional outcomes [25]. 
The Combined Assessment of Function 
and Survival (CAFS) has been proposed 
as a new endpoint for ALS to provide a 
more statistically robust measurement of 
clinical response than survival and 
functional data alone, and improve the 
likelihood of identifying a significant 
effect with treatment [10]. In fact, 
because a drug might have a 
disproportionate effect on function or 
survival, a trial designed with either 
survival or function as the primary 
outcome could fail if the wrong primary 
endpoint was chosen. Moreover, in 
analyzing trial outcomes, all functional 
outcome data are missing after a 
participant dies. For statistical analysis, 
these data must somehow be inferred but 
may not be valid and lead to biased 
results. As a matter of fact, if functional 
outcome scores are reported as a value of 
zero after death, the function may be 
underestimated. On the other side, if 
functional data is imputed using the last 
observation of the functional value 
obtained before death, the function will 
be overestimated. Thereby, CAFS is a 
novel endpoint that evaluates function 
while appropriately accounting for 
missing data due to deaths in ALS. It 
ranks each subject according to their 
outcome, with worst outcome assigned 
to the subject who dies first in the study 
and the best outcome assigned to the 
subject who survives with the least 
functional decline. In general, combined 
endpoints are advantageous because they 
more comprehensively estimate the 
overall benefit of a particular treatment, 
allow simultaneous analysis of multiple 
equally important outcome measures 
without relying on multiple comparisons 
or co-primary endpoints that can 
dramatically increase sample size, cost 
and time to obtain significant effects on 
both outcomes, offer additional 
statistical power and appropriately adjust 
for missing data owing to deaths and 
drop-outs. It also provides a balanced 
analysis of a drug that may have 
disparate effects on function and survival 
resulting in an appropriately attenuated 
mean CAFS rank for the magnitude of 
treatment group differences. [25] 
Muscle strength testing. There are three 
main measurement tools for muscle 
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strength. Firstly, it may be quantified 
using the composite manual muscle 
testing (MMT) scores, which usually 
involve averaging measures from 
multiple muscle groups using the 
Medical Research Council (MRC) 
muscle strength grading scale. Although 
there are alternative scales, as the Mayo 
Clinic Strength Scale, the MRC scale is 
the most widely used clinical strength 
scoring system, ranging from normal to 
the absence of contraction and has 
already been modified and improved 
[20].  
It is useful for clinical monitoring but 
more rigorous and objective quantitative 
techniques are recommended for future 
clinical trials since MRC scale is non-
linear and is particularly insensitive at 
detecting changes in mild weakness 
categories [10]. 
An additional quantitative method is 
hand-held dynamometry (HHD) which 
require minimal equipment, is rapid to 
perform and as comparable accuracy in 
weak muscles to the third measurement 
of muscle strength, the maximum 
voluntary isometric contraction (MVIC). 
Both HHD and MVIC provide relatively 
linear measurements at different muscle 
strengths. However, MVIC presents 
extensive equipment and training 
barriers that compromise its widespread 
application. MMT, HHD and MVIC 
demonstrate equivalent interrater 
reliability and reproducibility. [10] 
In a longitudinal study, the sensitivity to 
progressive weakness favoured MMT as 
opposed to MVIC mainly because as 
MMT is a simple, fast and inexpensive 
measure, investigators were able to 
evaluate and score more muscle than 
with MVIC which required special 
equipment and considerable time. [20] 
HHD may be an ideal balance between 
equipment and time costs and accuracy 
[10]. The simplest valid measure is often 
the best [20].  
As an alternative to the assessment of 
strength in individual muscles, there is 
the Tufts Quantitative Neuromuscular 
Exam (TQNE) that includes measures of 
bulbar motor function, respiration, timed 
hand movements and isometric muscle 
force in the upper and lower extremities.  
This composite motor assessment has 
proven to be both a reliable and a 
responsive index of disease progression. 
However, the score does not correlate 
with the patient’s perception of 
deterioration in physical health, which 
has implications for setting a MCID for 
clinical trials of ALS [20]. 
Efforts continue to be done in order to 
provide a more universal mean of 
assessing changes in muscle strength, 
remaining relatively independent of 
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examiner and patient factors such as 
baseline muscle strength.  
Respiratory muscle strength testing. 
Respiratory muscle strength has been 
assessed in most major ALS trials using 
vital capacity, SNIP and MVV.  
Vital capacity has been most thoroughly 
studied and has shown to decline by 
about 3% per month throughout much of 
the disease course. Its rate of decline is 
strongly correlated with survival, as 
would be expected given the close 
relationship between respiratory 
function and survival in ALS [19]. It can 
be measured through forced vital 
capacity (FVC), most commonly used, 
or slow vital capacity (SVC). A single 
FVC value obtained at baseline may 
serve as a clinically meaningful predictor 
of survival and disease progression [26]. 
Moreover, the decline in FVC seems to 
be linear in relation to the ALSFRS.[27] 
However, the accuracy of FVC 
measurement is highly dependent on the 
subject’s effort and cooperation and on 
the coaching of the evaluator [26], 
requiring hermetic sealing around the 
mouthpiece [27]. Therefore, its main 
limitations are the lack of reliability in 
patients with bulbar or facial weakness 
as well as being affected by submaximal 
effort. It may also not be sensitive to 
detect mild to moderate respiratory 
muscle weakness and might be affected 
by chest wall or airway factors. Supine 
FVC may be more sensitive that routine 
seated FVC measurement [10]. 
Despite these limitations, FVC 
measurement has been established as a 
recommended test for clinical trials and 
an important standard of ALS 
management. It is mainly employed as a 
secondary outcome measure [19] and 
remains a routine measurement in 
clinical care [10]. 
Because FVC assesses inspiratory 
muscle strength and does not take into 
account the important prognostic role of 
expiratory muscles, additional measures, 
such as SNIP and maximum expiratory 
pressure, may be also needed to assess 
the global respiratory function of ALS 
patients. [26] 
Maximum voluntary ventilation (MVV) 
is a less commonly used measure and 
assesses the total amount of air 
movements over a period of 12 s of deep 
and rapid breathing. As effort must be 
sustained, MVV reflects both respiratory 
muscle strength and endurance. It has not 
been well studied in ALS but it is 
suggested a rate of decline of about 4% 
per month based on a single longitudinal 
study. [19] 
The sniff nasal inspiratory pressure 
(SNIP) is independent of facial muscle 
strength and consequently an alternative 
for respiratory test in ALS [27]. It is 
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measured during a brief, maximal 
inspiratory effort. Both SNIP and a 
related measure, maximal inspiratory 
pressure (MIP), are reduced and decline 
over time. They have been infrequently 
used in ALS trials, [19] even though 
SNIP is recommended as a noninvasive 
measure of respiratory muscle weakness, 
since it can be performed reliably by 
most ALS patients, including those with 
orofacial weakness and is more sensitive 
to change in respiratory muscle strength 
than FVC, predicting respiratory failure 
more accurately than VC and MIP. The 
latter, has the advantages of using 
portable equipment and being more 
sensitive to early respiratory weakness 
than FVC but shares its lack of 
consistency in patients with bulbar and 
facial weakness [10]. 
SNIP balances ease of recording, 
reliability and accuracy and hence might 
be the optimal approach [10]. Its 
increased sensitivity to show impaired 
respiratory function when compared 
with FVC measurements, is most likely 
due to the fact that it correlates well with 
diaphragmatic strength and other 
muscles important for inspiratory 
function such as sternocleidomastoid 
muscle. However, in an exploratory trial 
aimed to assess the feasibility of SNIP as 
an outcome measure in phase III clinical 
trials, there was evidences that SNIP 
measurements in ALS patients might not 
be as reliable as previously suggested, 
since it appears to exist a learning effect 
when repeated sniff maneuvers are 
performed, which affects mean SNIP 
values obtained over time and resulted in 
significantly less decline of its 
measurements when compared with 
FVC or ALSFRS-R. Until the optimal 
number of repeated measures in clinical 
trials is determined, SNIP measures in 
ALS patients should be used with 
caution in trials. [27]  
Invasive techniques such as esophageal 
pressures are also accurate but 
impractical for regular use in the clinic 
[10]. 
Discussion 
 
The transition from phase II to phase III 
trials with positive results has been 
challenging.  The recurrent failures are 
probably attributable mostly to: a) the 
disease rarity and heterogeneity, which 
hamper the evaluation of drug effects; b) 
the limited knowledge of the exact 
pathways of neuron loss and the 
complexity of disease pathophysiology, 
meaning that a drug that only targets one 
of the pathogenic mechanisms will exert 
a small effect that easily can fail to be 
assessed in screening trials; c) 
uncertainty about safety and efficacy of 
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the delivery of the compounds to the 
CNS; d) lack of established animal 
models that faithfully recapitulate 
human pathology; e) ﬂawed trial designs 
and f) lack of validated, sensitive 
outcome measures and disease 
biomarkers.  
The choice of the outcome measures 
does definitely influence the conclusions 
obtained from clinical trials and this has 
been a recent topic of debate in ALS. 
Clinical trials should be conducted in 
order to detect changes felt to be 
clinically meaningful. A small effect as 
measured by a rating scale, even if 
statistically significant, may not be 
perceived as important either by the 
patients or physicians who care for them. 
Most of the negative results in clinical 
trials are due to the lack of statistical 
significance, which is explained by the 
reasons discussed previously. However, 
this does not mean that the obtained 
effect wouldn’t have a significantly 
impact in patient’s lives.  
The MCID (minimal clinically important 
difference) was introduced by the 
Regulatory Authorities to ensure that a 
positive outcome in a clinical trial was 
meaningful for the patient and impactful 
as a measure of disease modification. 
The difference between treated and 
placebo groups should be both 
statistically significant and greater than 
the defined MCID. However, defining 
the MCID is not as easy as it may seem, 
especially in such an heterogeneous 
disease as ALS. As shown in table 2, for 
almost all therapeutic efficacy measures, 
MCID isn’t defined yet.  
Phase III trials in ALS frequently use 
survival as the primary outcome but this 
requires large sample sizes and long 
study durations. Furthermore, survival 
measures may be insensitive to 
potentially significant changes in 
functional status and patient selection 
criteria factors may skew the phenotypes 
of included trial participants and thereby 
influence survival data. 
An alternative endpoint to survival is the 
use of functional measures. However, 
these measures often translate poorly 
into survival endpoints in phase III trials 
and although functional scales 
statistically predict survival, the 
correlation is not absolute.  
A treatment that significantly improves 
survival in ALS would obviously be of 
great value, although, conversely, a 
treatment that improves measures as 
ALSFRS-R, MMT or MUNE without 
changing survival may be of limited 
value.  
As one can infer from a cautious analysis 
of table 1, from the agents presented: 
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 riluzole proved to have an effect both 
clinically important and statistically 
significant; 
 pioglitazone and lithium carbonate 
failed to prove to be effective and 
even showed a potential detrimental 
effect;  
 the other agents tested actually 
showed small improvements in some 
of the key outcomes although not 
statistical significant. 
The results of the analysis combining the 
three trials of riluzole showed that the 
median survival benefit during 18 month 
follow-up was approximately 2 months, 
when taking riluzole, 100mg, daily. 
However, there was no evidence that 
riluzole exerted a therapeutic effect on 
motor function, lung function, 
fasciculations, muscle strength or motor 
symptoms, neither a proof of its efficacy 
in the late stages of ALS.  
In spite of its beneficial effects on 
survival, reservations on the clinical 
relevance of data observed with 
treatment of ALS with riluzole always 
persisted among the scientific 
community, especially due to the fact 
that the increase in survival obtained is 
less than the MCID established and due 
to the lack of concordance between the 
benefit on survival and the absence of 
benefit on functional scales. However, 
the failure to find any effect on 
functional endpoints does not affect the 
reliability of the survival results as the 
functional scales used have never been 
validated as a surrogate marker of 
survival. Nevertheless, there is no doubt 
that effects on functional endpoints, if 
established, would help to support the 
survival results – if the levels of 
statistical significance attached to the 
survival effects were marginal, this 
would have been an important point. 
However, the levels of statistical 
significance were sufficiently strong to 
stand on their own.  
Concerning the agents that showed small 
improvements in some of the key 
outcomes, there are interesting debatable 
topics that can be exploited from the 
analyses of their results. Indeed, a 
difference of 2 points in ALSFRS-R 
global score at 9 months, favouring the 
therapeutic arm, as it was obtained in 
olesoxime clinical trial, represents a 
decline of the score 0.22 points/month 
slower in treated patients, which is 
greater than 20% reduction in the slope 
of the score defined as the MCID. Even 
though this effect wasn’t sustained after 
18 months’ treatment, one should 
remember that an improved functional 
status during 9 months would be of great 
value in a disease with such poor 
prognosis as ALS.  An even greater 
effect on the decline of ALSFRS-R was 
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obtained in talampanel’s phase II trial. 
However, some authors state that phase 
II trials are too small to rule out false-
positive error and are deemed positive 
often based on non-significant trends in 
the same endpoints ultimately employed 
in Phase III. ALS trialists often include 
multiple efficacy outcome measures in 
phase II trials, reasoning that these are 
secondary or exploratory outcomes that 
could support efficacy data, and then 
throw aside primary outcome measures 
in favour of promising secondary 
outcome measures, reporting and 
interpreting trends lacking statistical 
power. This increases the likelihood of 
carrying drugs forward to later phase 
trials that will ultimately fail. 
Similar trends, although slightly smaller 
than the MCID established, in the slope 
of the ALSFRS-R were observed in 
ceftriaxone, rhEPO and UDCA clinical 
trials, which might suggest that those 
agents have a positive effect that was 
neglected and that could have had a 
significant impact even if just for a 
subpopulation of patients.   
As far as differences in survival are 
concerned, one cannot exclude that these 
differences aren’t the reflection of 
different rates of disease progression due 
to its known heterogeneity. 
Nevertheless, a 2% benefit of the 
estimated overall survival at 18 months 
(as seen in olesoxime CT) or 5% at 12 
months’ survival (as shown in rhEPO 
CT) shouldn’t be easily placed aside 
since the rate of survival at 12 months 
within the natural history of the disease 
is slightly more than 50%.        
Regarding muscle strength 
measurements, it is more difficult to 
infer which difference obtained would be 
clinically meaningful to the patient since 
they can assess muscle strength of 
different body segments, their 
progression with the natural history is 
not well characterized and they have a 
considerable degree of variability 
between clinical trials when used as key 
endpoints. No study has been performed 
linking a specific loss of strength to a 
change in a clinically meaningful 
activity. In addition, rate of decline in 
strength measures does not correlate 
with survival. In fact, respiratory muscle 
strength decline may occur at a different 
rate than decline in muscle strength in 
the extremities or face and this has 
dramatically different prognostic values.  
A 2-month delay, for 50% of the 
population (P50), at reaching <50% of 
predicted upright SVC or death, such the 
obtained with dexpramipexole, would 
mean that those patients would have a 
longer period free of respiratory 
complications, which are the main cause 
of death and of poorer quality of life.  
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Finally, and even though different 
questionnaires are used to assess Quality 
of Life (EUROQoL EQ-5D, SF-36, 
ALSAQ-5 or ALSAQ-40), these are 
valuable and reliable efficacy endpoints 
since they are subjective instruments and 
truly reflect what patients feel to be 
meaningful. A difference of 8 points 
favoring the treatment arm of a CT, as 
obtained with rhEPO, might be, even if 
statistically insignificant, an important 
difference considering the high 
morbidity of ALS. 
The paucity of positive clinical trials 
results might suggest that outcome 
measures are failing to assess small 
treatment effects.  
Conclusions 
 
The majority of CT failures, as 
previously discussed, are due to lack of 
statistical significance, which almost 
invariably leads to a wrong interpretation 
of the results. In fact, contrary to the 
formal statistical methods for analysing 
clinical trial data, that are widely 
accepted by the medical community, the 
interpretation and reporting of trial 
results from the perspective of clinical 
importance has not received similar 
emphasis. There is a historical tendency 
to consider clinical trial results that are 
statistically significant as also clinically 
important, and conversely, those with 
statistically non-significant results as 
being clinically unimportant. The 
concept of the MCID may be applied to 
detect clinically important changes of 
clinical rating scales but the approach to 
determine it based on the subjective 
opinions of clinician experts may be 
neglecting the patients perspective, 
which should be considered in the 
determination of a MCID. 
As important as determining MCID for 
survival and functional measures, which 
are undeniable the variants the 
researchers want to reach, a greater 
attention should be paid at Quality of 
Life Assessment Questionnaires as a key 
endpoint of efficacy on CT, given the 
significant morbidity of the disease. 
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